Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Expected to Announce Quarterly Sales of $157.21 Million

Equities analysts expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) to post sales of $157.21 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Supernus Pharmaceuticals’ earnings. The lowest sales estimate is $150.31 million and the highest is $164.10 million. Supernus Pharmaceuticals posted sales of $130.93 million during the same quarter last year, which would indicate a positive year over year growth rate of 20.1%. The business is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Supernus Pharmaceuticals will report full year sales of $680.14 million for the current financial year, with estimates ranging from $677.00 million to $683.28 million. For the next fiscal year, analysts forecast that the business will report sales of $610.80 million, with estimates ranging from $600.12 million to $629.18 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last announced its quarterly earnings results on Wednesday, April 13th. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.25). Supernus Pharmaceuticals had a net margin of 14.49% and a return on equity of 10.56%.

Several equities research analysts have recently issued reports on SUPN shares. Zacks Investment Research lowered Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, March 4th. StockNews.com started coverage on Supernus Pharmaceuticals in a report on Thursday, March 31st. They set a “hold” rating for the company.

Shares of Supernus Pharmaceuticals stock opened at $31.10 on Friday. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of 31.73 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.85 and a quick ratio of 2.59. Supernus Pharmaceuticals has a 52-week low of $23.15 and a 52-week high of $34.50. The stock has a 50-day simple moving average of $31.48 and a 200-day simple moving average of $30.65.

Several hedge funds have recently modified their holdings of the stock. Frontier Capital Management Co. LLC raised its stake in shares of Supernus Pharmaceuticals by 5.4% in the 1st quarter. Frontier Capital Management Co. LLC now owns 651,355 shares of the specialty pharmaceutical company’s stock valued at $21,052,000 after acquiring an additional 33,654 shares in the last quarter. Veriti Management LLC raised its stake in shares of Supernus Pharmaceuticals by 8.8% in the 1st quarter. Veriti Management LLC now owns 8,903 shares of the specialty pharmaceutical company’s stock valued at $288,000 after acquiring an additional 720 shares in the last quarter. Maryland State Retirement & Pension System raised its stake in shares of Supernus Pharmaceuticals by 2.2% in the 1st quarter. Maryland State Retirement & Pension System now owns 21,511 shares of the specialty pharmaceutical company’s stock valued at $695,000 after acquiring an additional 460 shares in the last quarter. Everence Capital Management Inc. bought a new position in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $272,000. Finally, Norges Bank bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at approximately $14,443,000.

Supernus Pharmaceuticals Company Profile (Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

See Also

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.